Clinical Trial Update: A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase II study assessing immunogenicity and safety of MVA-BN (IMVAMUNE) smallpox vaccine in subjects with atopic dermatitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• MVA-BN IMVAMUNE Smallpox Vaccine (Modified Vaccinia Ankara-based smallpox vaccine)

Snippet

Sponsor: Bavarian Nordic | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2019-01-09